Humatica, a private equity specialist adviser for portfolio organisational effectiveness, has advised private equity firm Intermediate Capital Group (ICG) on its investment in Lucid Group.
Founded in 2007, Lucid Group is a strategic healthcare communications company committed to advancing patient health outcomes through healthcare communications that improve the way patients and diseases are managed, and medicines are used. Lucid Group’s pioneering approaches have received industry-wide recognition and have consistently led to above industry growth.
With offices in the UK, US and Asia, Lucid now employs around 250 people. Lucid works in partnership with the world’s leading pharmaceutical and biotech organisations and has played a pivotal role in providing healthcare communication solutions for many of the industry’s innovative blockbuster assets.
Humatica was engaged by ICG to provide Organisational Due Diligence advice for this transaction.
Patrick Mina, Managing Partner UK of Humatica, says: “We were delighted to support ICG with pre-deal stage Organisational Due Diligence on Lucid where we helped to identify areas of focus for the value creation plan. We are proud to have assisted ICG on this transaction and look forward to supporting their growth plans in the future.”
Peter Kirtley, ICG’s Managing Director, adds: “ICG is a leading global alternative asset manager, with a long and successful track record of providing capital to support founder-led growing businesses like Lucid Group. We have admired Lucid Group and its reputation within the industry for many years. Through our partnership, together, we can leverage Lucid’s ambition and our sector expertise to build a truly global healthcare communications organisation.”
The Humatica team was led by Patrick Mina, Managing Partner UK and Head of the London office, supported by Humatica Directors Valentina Pozzobon and Andreas Knobloch.
